News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–36
Matches
82
Sources here
17
Companies here
6
Search results Stored financial headlines

Active search

82 matching headlines

Ticker or company: ENELMain company stories
Clear

Genelux (GNLX) deepens losses while funding Phase 3 cancer trial and warning on cash runway

Genelux (GNLX), a clinical-stage oncology biotech company, reported a widening net loss of $9.5 million for Q2 2026 and $18.4 million for the first half of 2026, primarily due to increased R&D expenses for its Phase 3 Olvi-Vec cancer trial. Despite a recent $18.5 …

GNLX main company
Sharemaestro market context Trend signal active 52 weeks -27.5% GNLX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

GENELUX Corp 6M 2026: Revenue $0 Net loss $(18.4M), EPS $(0.41) — 10-Q Summary

GENELUX Corp reported its financial results for the six months ended June 30, 2026, showing no revenue, a net loss of $(18.4M), and diluted EPS of $(0.41). The company's net loss worsened compared to the prior year, primarily due to increased clinical and regulatory …

GNLX main company
Sharemaestro market context Trend signal active 52 weeks -27.5% GNLX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

Genelux Corporation announced its second-quarter 2026 financial results and provided business updates, including anticipated topline data from its Phase 3 OnPrime/GOG-3076 ovarian cancer trial in the second half of 2026. The company reported $18.7 million in cash, cash equivalents, marketable securities, and restricted cash …

GNLX main company
Sharemaestro market context Trend signal active 52 weeks -27.5% GNLX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Enel Chile SA (ENIC) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Enel Chile SA (ENIC), indicating a current earnings forecast score of 7.33 and ranking 26th in the Electric Utilities & IPPs industry. Based on analysis from 3 analysts, the average price target is $3.90, with a consensus …

ENIC main company
Sharemaestro market context Trend signal active 52 weeks +36.1% ENIC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Genelux Corp (GNLX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Genelux Corp (GNLX) has an earnings forecast score of 8.00, placing it 171st in the Biotechnology & Medical Research industry. Analysts have set an average price target of $18.00 for GNLX, with a range from $10.00 to $31.00. Based on ratings from 6 analysts, …

GNLX main company
Sharemaestro market context Trend signal active 52 weeks -27.5% GNLX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Genel jumps 13% after rejecting £202m cash approach from DNO - UPDATE

Genel jumps 13% after rejecting £202m cash approach from DNO - UPDATE Proactive uses images sourced from Shutterstock Genel Energy PLC (LSE:GENL, FRA:4VL, OTC:GEGYY) shares jumped 13% to 56.6p after it rejected a £202 million cash approach from DNO, its Norwegian rival in the …

GENL main company
Sharemaestro market context Price above Trend Line 52 weeks +4.6% · Next-week setup negative 36.0% GENL stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Insiders Sold Genelux At US$3.34, Meanwhile Stock Sits Near US$2.51

Despite a recent 11% drop in Genelux Corporation's value, insiders who sold US$181k worth of stock over the last year would have been better off holding, as their average selling price of US$3.34 is higher than the current US$2.51 share price. There have been …

GNLX main company
Sharemaestro market context Trend signal active 52 weeks -27.5% GNLX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Renaissance Technologies LLC Sells 374,400 Shares of Enel Chile S.A. $ENIC

Renaissance Technologies LLC has reduced its stake in Enel Chile S.A. (NYSE:ENIC) by selling 374,400 shares, now holding 2.69 million shares valued at approximately $10.6 million. Despite this sale, other institutional investors have increased their positions in the company. Enel Chile reported quarterly revenue …

ENIC main company
Sharemaestro market context Trend signal active 52 weeks +36.1% ENIC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Genelux Corp expected to post a loss of 20 cents a share - Earnings Preview

Genelux Corp (GNLX) is expected to report a loss of 20 cents per share in its upcoming earnings. This forecast is based on information from Refinitiv. The article provides an earnings preview for the company.

GNLX main company
Sharemaestro market context Trend signal active 52 weeks -27.5% GNLX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Enel Chile S.A. 2026 Q2 - Results - Earnings Call Presentation (NYSE:ENIC) 2026-08-01

Enel Chile S.A. (NYSE:ENIC) has published its slide deck in conjunction with its Q2 2026 earnings call. The article, provided by SA Transcripts, highlights the company's Q2 results presented on August 1, 2026. This content is intended for investors following Enel Chile S.A.'s financial …

ENIC main company
Sharemaestro market context Trend signal active 52 weeks +36.1% ENIC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Enel Chile Lifts H1 2026 Profit and Advances Battery Storage Project

Enel Chile reported a 10.7% year-on-year increase in consolidated net income to US$272 million for the first half of 2026, driven by operating improvements and cost reductions despite flat revenues. The company also began construction of the Azabache BESS battery energy storage system, a …

ENIC main company
Sharemaestro market context Trend signal active 52 weeks +36.1% ENIC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

ETFs Investing in Enel Chile SA Sponsored ADR Stocks

This article lists several ETFs that hold Enel Chile SA Sponsored ADR stocks, providing details such as market value, weight, issuer, expense ratio, and AUM for each fund. The ETFs cover various investment strategies including passive, theme-based, and total market approaches, offering different opportunities …

ENIC main company
Sharemaestro market context Trend signal active 52 weeks +36.1% ENIC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Price to book forward of Enel Chile SA – BCS:ENELCHILE

The article focuses on the "Price to book forward" financial metric for Enel Chile SA (BCS:ENELCHILE), a utility company listed on the Santiago Stock Exchange. It provides a snapshot of the company's financial data as of the market close, indicating no trades occurred. The …

ENIC main company
Sharemaestro market context Trend signal active 52 weeks +36.1% ENIC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Genelux Corp (GNLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Genelux Corp (GNLX), detailing its price momentum score of 3.33 and its trading range between a resistance of $3.15 and support of $2.75. It reviews various technical indicators like MACD, RSI, and Moving Averages, concluding with a …

GNLX main company
Sharemaestro market context Trend signal active 52 weeks -27.5% GNLX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Genelux Corp (GNLX) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Genelux Corp (GNLX), assigning it a TradingKey financial score of 7.03, ranking 153 out of 384 in the Biotechnology & Medical Research industry. The company's financial status is deemed stable with low operating efficiency. The analysis …

GNLX main company
Sharemaestro market context Trend signal active 52 weeks -27.5% GNLX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Genelux Corp (GNLX) Institutional Confidence

The article analyzes the institutional confidence score for Genelux Corp (GNLX), which is currently 3.00, ranking it 192 out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 14.81% quarter-over-quarter, reaching 30.96%. James Simons is identified as …

GNLX main company
Sharemaestro market context Trend signal active 52 weeks -27.5% GNLX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

ENIC|Enel Chile SA|Precio:4.555|Variación %:+0.195

This article provides real-time stock information for Enel Chile SA (ENIC), including its current price of $4.555, a 4.47% increase, and key financial metrics. It highlights the company's strong fundamentals and high growth potential, fair valuation, and high institutional ownership. Analysts have rated Enel …

ENIC main company
Sharemaestro market context Trend signal active 52 weeks +36.1% ENIC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Genelux Corp (GNLX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Genelux Corp (GNLX), highlighting its current stock performance and risk score. GNLX has a risk assessment score of 1.61, ranking 279 out of 384 in the Biotechnology & Medical Research industry, with a beta of 0.54, indicating …

GNLX main company
Sharemaestro market context Trend signal active 52 weeks -27.5% GNLX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Enel Chile SA (ENIC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Enel Chile SA (ENIC), noting that relevant data regarding business segments and regional revenue and profit contribution have not yet been disclosed by the company. It displays current stock information including its market cap and P/E ratio, …

ENIC main company
Sharemaestro market context Trend signal active 52 weeks +36.1% ENIC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context